TGFB1 and systemic sclerosis: In control serum, 75.2% of TGFβ was bioactive, whereas in the SSc serum, only 43.4% of TGFβ was bioactive, which thus corresponds to a difference in latency of  24.8 versus 56.6 percent (Fig. 1c).